Table 2 SUVmax and T/N ratio of gliomas
Characteristic | MET | FLT | ||
|---|---|---|---|---|
SUVmax, median (IQR) | T/N ratio, median (IQR) | SUVmax, median (IQR) | T/N ratio, median (IQR) | |
Grade | ||||
II (n = 12) | 2.99 (1.94–4.23) | 2.51 (1.86–3.13) | 0.49 (0.30–0.69) | 2.24 (1.69–2.62) |
III (n = 24) | 5.92 (4.65–6.52) | 5.03 (3.58–6.39) | 1.29 (0.90–1.49) | 6.25 (4.59–8.69) |
IV (n = 45) | 6.21 (4.45–7.66) | 5.99 (4.64–7.39) | 2.77 (1.92–3.29) | 15.24 (11.11–20.49) |
IDH status | ||||
Mutant (n = 29) | 4.83 (3.04–6.37) | 3.6 (2.87–5.59) | 0.93 (0.47–1.44) | 4.18 (2.28–6.39) |
Wildtype (n = 52) | 6.11 (4.63–7.56) | 5.91 (4.54–7.35) | 2.59 (1.61–3.24) | 14.7 (8.98–20.39) |
Histology and subtype | ||||
DA (n = 9) | 2.77 (1.86–3.69) | 2.03 (1.83–2.97) | 0.46 (0.23–0.57) | 2.35 (1.69–2.60) |
IDH-mut (n = 8) | 2.76 (1.75–4.01) | 2.45 (1.85–3.26) | 0.45 (0.23–0.59) | 2.07 (1.69–2.62) |
IDH-wt (n = 1) | 2.85 | 1.83 | 0.57 | 2.48 |
OD (n = 3) | 3.68 (3.31–4.29) | 2.86 (2.51–3.23) | 0.59 (0.49–0.73) | 2.14 (1.91–3.42) |
AA (n = 14) | 5.22 (4.06–5.84) | 4.65 (3.25–5.99) | 1.37 (0.89–1.47) | 7.16 (4.77–9.41) |
IDH-mut (n = 6) | 4.50 (3.14–5.67) | 3.28 (2.99–5.19) | 0.99 (0.68–1.35) | 4.9 (3.48–6.98) |
IDH-wt (n = 8) | 5.76 (5.26–5.83) | 5.41 (4.11–6.20) | 1.66 (0.90–2.36) | 8.1 (6.58–14.53) |
AO (n = 10) | 6.91 (5.14–7.79) | 5.07 (4.72–7.21) | 1.18 (0.97–1.49) | 5.82 (4.26–6.79) |
GBM (n = 45) | 6.21 (4.45–7.66) | 5.99 (4.64–7.39) | 2.77 (1.92–3.29) | 15.24 (11.11–20.46) |
IDH-mut (n = 2) | 5.44 (4.64–6.24) | 5.6 (5.59–5.60) | 1.90 (1.74–2.06) | 14.58 (14.47–14.69) |
IDH-wt (n = 43) | 6.25 (4.58–7.71) | 6.19 (4.63–7.41) | 2.81 (1.95–3.32) | 15.65 (10.35–20.77) |